top of page

CO-FOUNDERS

Chief Development Officer Tiffany Whitlow and Chief Executive Officer Del Smith, Ph.D., founded Acclinate in 2017 after both personally experiencing the disparity in healthcare studies and education for minority communities. Del Smith has extensive management and leadership experience in healthcare, IT, education, and government. His experience includes three years with the US Army, five years as Founder and CEO of FoxWise Technologies USA, and seven years as Associate Professor of Management and Director of the Center for Urban Entrepreneurship with Rochester Institute of Technology - Saunders College of Business. Del holds a BBA from Faulkner University, an MS from The Sorrell College of Business at Troy University, and a PhD in Management from the University of Alabama.  

 

Tiffany has over five years of experience serving as both President of Driven Solutions and Vice President of Board of Directors for Nexus Energy Center. Tiffany also serves as a Board Member for the nonprofits Urban Engine and United Way of Madison County. 

Tiffany Whitlow (CDO) and Del Smith (CEO) 

Tiffany Whitlow (CDO) and Del Smith (CEO) 

Acclinate is a digital health analytics platform that assists healthcare organizations in engaging communities of color to increase representation and diversity of clinical trials and genomic research. Acclinate's engaged community of 21K+ members and machine-learning based platform helps healthcare companies decrease the cost of drug development, increase the speed of drug approval, aid in the discovery of new drugs, and integrate with virtual clinical trials.

COMPANY

MILESTONES

  • Closed $3.5M Series Seed raise with a post-money valuation of $20M (November 2022) 

  • Founded in 2017 

KEY HIGHLIGHTS

  • Inc. “Best in Business” for digital health platform NOWINCLUDED in the Southeast Region category (2022) 

  • Awardee in "Johnson & Johnson Innovation's QuickFire Challenge” (2022) 

  • Winner of "DPHARM Idol Disrupt” (2022) 

  • Partnership with Trialbee to enhance equitable clinical trial participation 

  • Investors include Black Star Fund, Google for Startups Accelerator, Overline, Avalanche VC, and Techstars

bottom of page